Cosmetic Ingredient Review vs SCCS: Two Ways to Do a Cosmetic Ingredient Data Review

A formulator checking whether an ingredient is accepted for use will run into two very different bodies of work: the Cosmetic Ingredient Review (CIR) in the United States, and the Scientific Committee on Consumer Safety (SCCS) in the European Union. Both publish safety assessments of cosmetic ingredients. Neither is a law. Confusing the two, or assuming either one issues a binding verdict, is a common source of mislabeled claims. This article sets out what each body is, what its outputs mean, and how their conclusions on the same substance can diverge in practice.

The Cosmetic Ingredient Review: origin and funding

CIR was established in 1976. Its own description of its history states it was set up "by the industry trade association (then the Cosmetic, Toiletry, and Fragrance Association, now the Personal Care Products Council), with the support of the U.S. Food and Drug Administration and the Consumer Federation of America." It is industry-funded, but CIR states that its review process is run independently of the Personal Care Products Council and the cosmetics industry that funds it.

Ingredient reviews are carried out by the CIR Expert Panel for Cosmetic Ingredient Safety. Per CIR's own account of its process, the Panel has seven voting members, who are physicians and scientists, plus three non-voting liaison members representing government (FDA), consumers (the Consumer Federation of America) and industry. CIR states that Expert Panel members must meet the same conflict-of-interest requirements as members of FDA advisory committees.

CIR's conclusion categories

CIR describes its process as reaching one of four possible outcomes for an ingredient, or group of related ingredients, under review:

• Safe — the ingredient is safe in the practices of use (product categories) and concentrations of use documented in the assessment.
• Safe with qualifications — the ingredient can be used safely, but only under stated conditions, which CIR says frequently relate to maximum concentration, and may also cover rinse-off versus leave-on use and other restrictions.
• Unsafe — the ingredient has specific adverse effects that make it unsuitable for use in cosmetics.
• Insufficient data — the Panel does not state whether the ingredient is safe or unsafe; it describes a situation where the available data do not support a safety conclusion, and identifies the specific data that would let it complete the assessment.

A CIR report is therefore not a single yes/no rating. It is a conclusion tied to specific concentrations and use patterns, and an ingredient can sit in the "insufficient data" category for years while awaiting the studies the Panel has asked for.

CIR conclusions have no legal force in the US

CIR is not a government agency and its conclusions are not regulations. The US has no general EU-style pre-market approved-ingredient list; FDA's own cosmetic-ingredient page, referenced on the jurisdiction record at cosingchecker.com/regulations/us/, describes a small set of ingredient-specific prohibitions and restrictions under 21 CFR rather than a positive list. An FDA liaison sits on the CIR Expert Panel as a non-voting member, which is a channel of awareness, not an approval mechanism. A "safe as used" CIR conclusion does not itself change what is lawful to sell; a company can, in principle, market a product with an ingredient CIR has called unsafe or insufficiently supported, subject to FDA's general adulteration and misbranding authority. Readers should treat a CIR conclusion as an independent expert assessment that FDA and industry may act on, not as a rule with the force of law.

How to find a CIR report

CIR publishes its finished assessments, and the underlying meeting records, on cir-safety.org. Each ingredient or ingredient group has a numbered safety assessment (an original report, and often a later "amended" or re-review report when new data arrive), with a stated conclusion, the concentration and use conditions behind it, and the supporting data summary. Because CIR is a third-party body, cosingchecker.com/sources/ lists it, alongside FDA, EUR-Lex, ECHA and the other regulators the site draws from, as a source to consult directly rather than a dataset the site reproduces.

The EU's Scientific Committee on Consumer Safety

SCCS is one of the European Commission's non-food scientific committees. According to the Commission's own page for the Committee, SCCS provides opinions on the health and safety risks — chemical, biological, mechanical and other physical — of non-food consumer products and services, including cosmetics, tattooing and artificial sun tanning. Unlike CIR, SCCS does not run an open program of reviewing whatever ingredients its members choose. The Commission's page states the Committee "usually produces its reports in response to a specific request" — a Commission mandate — though it can also issue opinions through a stakeholder dialogue procedure, or publish self-initiated statements on specific topics.

In practice, a mandate is triggered by a concern: a Member State restriction proposal, new toxicological data, a substance newly classified as carcinogenic, mutagenic or toxic to reproduction (CMR) under the CLP Regulation, or industry data submitted in support of continued use. SCCS then produces a formal Opinion, addressed to the Commission, on whether and under what conditions the substance is safe in cosmetic products.

The Notes of Guidance and the margin of safety

SCCS assessments follow a standing methodology document, the "SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation," now in its 12th revision, with a separate guidance document on nanomaterials in cosmetics. The Notes of Guidance set out what toxicological data SCCS expects (irritation, sensitisation, genotoxicity, repeated-dose toxicity, and so on) and how the Committee turns that data into a numeric safety judgment: the margin of safety (MoS).

The MoS is the ratio between a toxicological point of departure — usually a No Observed Adverse Effect Level (NOAEL) from an animal repeated-dose study, or a benchmark dose lower confidence limit where one can be derived — and the Systemic Exposure Dose (SED), an estimate of how much of the substance actually reaches the body under realistic use. The Notes of Guidance treat an MoS of 100 or higher as the threshold for adequate safety, built from a 10x allowance for extrapolating from animals to humans and a further 10x allowance for variability between humans. An MoS below 100 signals that exposure under the proposed use is too close to the level associated with adverse effects in the underlying study.

From SCCS opinion to EU annex amendment

SCCS opinions feed directly into the annexes of Regulation (EC) No 1223/2009 — the prohibited-substance list (Annex II), the restricted-substance list (Annex III), and the positive lists for colorants, preservatives and UV filters (Annexes IV, V and VI). The Commission uses SCCS's conclusion as the scientific basis for a Commission Regulation amending the relevant annex: adding a substance to Annex II if SCCS finds no safe use, or setting the concentration limits and warning text in Annex III, V or VI if SCCS finds a use level supported by an adequate margin of safety. For substances newly classified as CMR, the rule itself is in Article 15: they are prohibited unless the SCCS has evaluated the use and found it safe, with further conditions for categories 1A and 1B. Article 31(1) is the general mechanism the Commission then uses, after consulting the SCCS, to amend Annexes II to VI and give that outcome effect. The record on cosingchecker.com/annex/ for any Annex II-VI entry links the underlying SCCS opinions where the site has matched them to that entry, alongside the amending EU regulation that gave the annex change legal effect.

Where the two systems diverge

The practical differences follow from the above. CIR reviews an ingredient on its own initiative and publishes a conclusion that is persuasive but not binding; SCCS reviews an ingredient only when the Commission mandates it, and its opinion is a direct input to a legally binding EU annex amendment. CIR's scope is the US cosmetics market; SCCS's scope is the EU (and, through incorporation, related markets such as the UK's retained regulation). CIR issues one of four standard conclusion labels per ingredient; SCCS issues a substance-specific opinion built around a calculated margin of safety, which the Commission then translates into a concentration limit or a ban.

Two ingredients, two systems

Parabens illustrate how the two processes can reach compatible outcomes through different mechanics. CIR's Expert Panel reviewed 21 parabens and, in its 2020 amended assessment, concluded that 20 of the 21 are safe as used in cosmetics provided the sum of all parabens in a formulation does not exceed 0.8%. On the EU side, the CosIng Checker record for Annex V entry 12a shows butylparaben, propylparaben and their sodium and potassium salts permitted as preservatives at up to 0.14% (as acid) for the individual substances, or 0.8% for the combined total with the related entry 12, plus a labelling requirement against use in the nappy area of children under three. That entry lists seven SCCS and predecessor-committee opinions on parabens behind the current EU limits. Separately, five other, longer-chain and branched parabens — isopropylparaben, isobutylparaben, phenylparaben, benzylparaben and pentylparaben — were moved to Annex II (banned) by Regulation (EU) No 358/2014, following an SCCS opinion that found no adequate safety data to support their continued use; CIR's own review covered those same substances within its 21-paraben group.

Triclosan shows the two systems reaching a similar outcome on timing but through separate routes. CIR's Final Report on triclosan, published in December 2010, reviewed antimicrobial-resistance and genotoxicity data as part of a wider ingredient-safety literature review. On the EU side, the CosIng Checker record for Annex V entry 25 shows triclosan permitted as a preservative up to 0.3%, restricted to a defined list of product types (toothpaste, hand and body soap, non-spray deodorants, face powders and certain nail products), with a mandatory child-age warning on toothpaste. That entry lists five SCCS and predecessor-committee opinions, the most recent addressing endocrine-disrupting-property concerns; the current concentration and product-type restrictions were set by Regulation (EU) 2024/996.

What this means for reading a safety claim

A CIR "safe as used" conclusion and an SCCS opinion behind an EU annex entry are both real, citable pieces of expert review — but neither is interchangeable with the other, and neither is a blanket safety certificate. A CIR conclusion is scoped to the concentrations and use categories in that specific report. An SCCS opinion is scoped to the mandate the Commission gave it, and its practical effect is whatever concentration limit or prohibition the Commission subsequently wrote into the annex — which is the legally binding instrument, not the opinion itself. CosIng Checker records the annex text and the SCCS opinions a given EU entry cites; it does not host CIR reports or reproduce FDA determinations, and an ingredient absent from a CosIng Checker jurisdiction page reflects the state of that jurisdiction's published rules, not a judgment on the ingredient's safety.

Sources

• CIR — About CIR (establishment, funding, history) — https://www.cir-safety.org/about
• CIR — How Does CIR Work? (Expert Panel composition, four conclusion categories, FDA liaison) — https://www.cir-safety.org/how-does-cir-work
• CIR — Amended Safety Assessment of Parabens as Used in Cosmetics, 2020 — https://www.cir-safety.org/sites/default/files/Parabens_0.pdf
• CIR — Final Report on the Safety Assessment of Triclosan, December 2010 — https://www.cir-safety.org/sites/default/files/FR569.pdf
• European Commission — Scientific Committee on Consumer Safety (SCCS): mandate and procedure — https://health.ec.europa.eu/scientific-committees/scientific-committee-consumer-safety-sccs_en
• European Commission / SCCS — Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation, 12th revision — https://health.ec.europa.eu/system/files/2023-12/sccs_o_273_final.pdf
• EUR-Lex — Regulation (EC) No 1223/2009 on cosmetic products (Article 15, Article 31, Annexes II-VI) — https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32009R1223
• EUR-Lex — Commission Regulation (EU) No 358/2014 amending Annexes II and V (parabens) — https://eur-lex.europa.eu/eli/reg/2014/358/oj
• EUR-Lex — Commission Regulation (EU) 2024/996 amending Annex V (triclosan) — https://eur-lex.europa.eu/eli/reg/2024/996/oj
• FDA — Cosmetic Ingredients — https://www.fda.gov/cosmetics/cosmetic-products-ingredients/cosmetic-ingredients
• CosIng Checker — Annex V entry 12a (butylparaben/propylparaben) — https://cosingchecker.com/annex/v/v-12-a-butylparabenpropylparabensodium-propoylparabensodium-butylparabenpotassium-butylparabenpotassium-propylparaben/
• CosIng Checker — Annex II entry 1374 (isopropylparaben) — https://cosingchecker.com/annex/ii/ii-1374-isopropyl-4-hydroxybenzoate-inci-isopropylparaben-sodium-salt-or-sats-of-isopropylparaben/
• CosIng Checker — Annex V entry 25 (triclosan) — https://cosingchecker.com/annex/v/v-25-triclosan/
• CosIng Checker — API stats endpoint (coverage figures) — https://cosingchecker.com/api/v1/stats/
• CosIng Checker — Sources — https://cosingchecker.com/sources/
• CosIng Checker — US jurisdiction page — https://cosingchecker.com/regulations/us/